SFX by Ex Libris Inc.

Title:	Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial
Source:	Blood [0006-4971] Brümmendorf, Tim yr:2020

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Gambacorti Passerini, C. "Bosutinibversusimatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial." British journal of haematology 168.1 (2015): 69-81.
description	2.	"Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials." Blood : journal of the American Society of Hematology. 138.Supplement 1: 2550-2550.
description	3.	Takahashi, K. "A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase." Cancer 122.21 (2016): 3336-3343.
description	4.	Cortes, Jorge E. "Long-term Bosutinib For Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib Plus Dasatinib and/or Nilotinib." American journal of hematology (2016): 1206-1214.
description	5.	Hochhaus, A. "Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial." Leukemia 30.5 (2016): 1044-1054.
description	6.	Cortes, Jorge E. "Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial." Journal of clinical oncology 30.28 (2012): 3486-3492.
description	7.	Khoury, Jorge J. "Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure." Blood 119.15 (2012): 3403-3412.
description	8.	Kantarjian, Hagop M. "Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial." Lancet oncology 12.9 (2011): 841-851.
description	9.	Nakamae, H. "Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report." International Journal of Hematology (2017): 792-804.
description	10.	Tomono, K. "Involvement of a Proton-Coupled Organic Cation Antiporter in the Blood-Brain Barrier Transport of Amantadine." Biopharmaceutics & drug disposition 37.6 (2016): 323-335.
description	11.	Sasaki, K. "Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis." Cancer 122.23 (2016): 3650-3656.
description	12.	Brümmendorf, Tim H. "Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib." British journal of haematology 172.1 (2015): 97-110.
description	13.	Simonsson, B. "Epidemiology of chronic myeloid leukaemia: an update." Annals of hematology 94.2 (2015): 241-247.
description	14.	Gambacorti Passerini, C. "Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up." American journal of hematology 89.7 (2014): 732-42.
description	15.	An, X. "BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review." Leukemia Research 34.10 (2010): 1255-1268.
description	16.	Boschelli, F. "Bosutinib: A review of preclinical studies in chronic myelogenous leukaemia." European journal of cancer 46.10 (2010): 1781-1789.
description	17.	Saglio, G. "Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia." New England Journal of Medicine, The 362.24 (2010): 2251-2259.
description	18.	Rix, U. "Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells." Leukemia 23.3 (2009): 477-485.
description	19.	Berman, E. "Altered bone and mineral metabolism in patients receiving imatinib mesylate." The New England journal of medicine 354.19 (2006): 2006-13.
description	20.	O'Hare, T. "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants." Cancer research 65.11 (2005): 4500-5.